Skip to main content
Top
Published in: Journal of Diabetes & Metabolic Disorders 1/2017

Open Access 01-12-2017 | Review article

Glucose variability for cardiovascular risk factors in type 2 diabetes: a meta-analysis

Authors: Shuang Liang, Hang Yin, Chunxiang Wei, Linjun Xie, Hua He, Xiaoquan Liu

Published in: Journal of Diabetes & Metabolic Disorders | Issue 1/2017

Login to get access

Abstract

Aims

It is consensus that glucose variability (GV) plays an important role in maccomplications of type 2 diabetes, but whether GV has a causal role is not yet clear for cardiovascular disease (CVD). This study sought to explore the effect on GV for CVD risk factors with type 2 diabetes.

Methods

The systematic literature search was performed to identify all GV and CVD risk factors, including total cholesterol (TC), LDL cholesterol (LDL-C), triglyceride (TG), HDL cholesterol (HDL-C), Body Mass Index (BMI), waist circumference (WC), High-Sensitivity C-reactive protein (Hs-CRP), Homeostasis model assessment (HOMA) and carotid intima-media thickness (IMT). Preferred Reporting Items was synthesized for Systematic reviews and Meta Analyses guideline. And the pooled analyses were undertaken using Review Manager 5.3.

Results

Twenty two studies were included with a total of 1143 patients in high glucose variability group (HGVG) and 1275 patients low glucose variability group (LGVG). Among these selected CVD risk factors, HOMA-IR and reduced IMT were affected by GV. HOMA-IR level was significantly lower in LGVG than in HGVG (MD = 0.58, 95% CI: 0.26 to 0.91, P = 0.0004), with evidence of heterogeneity between studies (I2 = 0%; P = 0.47).
Reduced IMT level was significantly lower in LGVG than in HGVG (SMD = 0.28, 95% CI: 0.09 to 0.47, P = 0.003), with evidence of heterogeneity between studies (I2 = 0%; P = 0.48). However, the others were no significant statistical difference.

Conclusions

Among these selected CVD risk factors in type 2 diabetes, minimizing GV could improve insulin resistance and reduced IMT, consistent with a lowering in risk of CVD.
Appendix
Available only for authorised users
Literature
1.
go back to reference Buse JB, Ginsberg HN, Bakris GL, Clark NG, Costa F, Eckel R, Fonseca V, Gerstein HC, Grundy S, Nesto RW, et al. Primary prevention of cardiovascular diseases in people with diabetes mellitus - a scientific statement from the American Heart Association and the American Diabetes Association. Circulation. 2007;115(1):114–26.CrossRefPubMed Buse JB, Ginsberg HN, Bakris GL, Clark NG, Costa F, Eckel R, Fonseca V, Gerstein HC, Grundy S, Nesto RW, et al. Primary prevention of cardiovascular diseases in people with diabetes mellitus - a scientific statement from the American Heart Association and the American Diabetes Association. Circulation. 2007;115(1):114–26.CrossRefPubMed
3.
go back to reference Arca M, Pigna G, Favoccia C. Mechanisms of diabetic dyslipidemia: relevance for atherogenesis. Curr Vasc Pharmacol. 2012;10(6):684–6.CrossRefPubMed Arca M, Pigna G, Favoccia C. Mechanisms of diabetic dyslipidemia: relevance for atherogenesis. Curr Vasc Pharmacol. 2012;10(6):684–6.CrossRefPubMed
4.
go back to reference Hall JE, Jones DW, Kuo JJ, da Silva A, Tallam LS, Liu J. Impact of the obesity epidemic on hypertension and renal disease. Curr Hypertens Rep. 2003;5(5):386–92.CrossRefPubMed Hall JE, Jones DW, Kuo JJ, da Silva A, Tallam LS, Liu J. Impact of the obesity epidemic on hypertension and renal disease. Curr Hypertens Rep. 2003;5(5):386–92.CrossRefPubMed
5.
go back to reference Cushman M, Arnold AM, Psaty BM, Manolio TA, Kuller LH, Burke GL, Polak JF, Tracy RP. C-reactive protein and the 10-year incidence of coronary heart disease in older men and women: the cardiovascular health study. Circulation. 2005;112(1):25–31.CrossRefPubMed Cushman M, Arnold AM, Psaty BM, Manolio TA, Kuller LH, Burke GL, Polak JF, Tracy RP. C-reactive protein and the 10-year incidence of coronary heart disease in older men and women: the cardiovascular health study. Circulation. 2005;112(1):25–31.CrossRefPubMed
6.
go back to reference Riddle MC. Effects of intensive glucose lowering in the management of patients with type 2 diabetes mellitus in the action to control cardiovascular risk in diabetes (ACCORD) trial. Circulation. 2010;122(8):844–6.CrossRefPubMedPubMedCentral Riddle MC. Effects of intensive glucose lowering in the management of patients with type 2 diabetes mellitus in the action to control cardiovascular risk in diabetes (ACCORD) trial. Circulation. 2010;122(8):844–6.CrossRefPubMedPubMedCentral
7.
go back to reference Stratton IM, Adler AI, Neil HA, Matthews DR, Manley SE, Cull CA, Hadden D, Turner RC, Holman RR. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ (Clinical research ed). 2000;321(7258):405–12.CrossRef Stratton IM, Adler AI, Neil HA, Matthews DR, Manley SE, Cull CA, Hadden D, Turner RC, Holman RR. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ (Clinical research ed). 2000;321(7258):405–12.CrossRef
8.
go back to reference Gerstein HC, Miller ME, Byington RP, Goff DC Jr, Bigger JT, Buse JB, Cushman WC, Genuth S, Ismail-Beigi F, Grimm RH Jr, et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med. 2008;358(24):2545–59.CrossRefPubMed Gerstein HC, Miller ME, Byington RP, Goff DC Jr, Bigger JT, Buse JB, Cushman WC, Genuth S, Ismail-Beigi F, Grimm RH Jr, et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med. 2008;358(24):2545–59.CrossRefPubMed
9.
go back to reference Patel A, MacMahon S, Chalmers J, Neal B, Billot L, Woodward M, Marre M, Cooper M, Glasziou P, Grobbee D, et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med. 2008;358(24):2560–72.CrossRefPubMed Patel A, MacMahon S, Chalmers J, Neal B, Billot L, Woodward M, Marre M, Cooper M, Glasziou P, Grobbee D, et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med. 2008;358(24):2560–72.CrossRefPubMed
10.
go back to reference Duckworth W, Abraira C, Moritz T, Reda D, Emanuele N, Reaven PD, Zieve FJ, Marks J, Davis SN, Hayward R, et al. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med. 2009;360(2):129–39.CrossRefPubMed Duckworth W, Abraira C, Moritz T, Reda D, Emanuele N, Reaven PD, Zieve FJ, Marks J, Davis SN, Hayward R, et al. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med. 2009;360(2):129–39.CrossRefPubMed
11.
go back to reference Dadlani V, Kudva YC. Assessment of Interday glucose variability in type 2 diabetes. Diabetes Technol Ther. 2017;19(8):443–5.CrossRefPubMed Dadlani V, Kudva YC. Assessment of Interday glucose variability in type 2 diabetes. Diabetes Technol Ther. 2017;19(8):443–5.CrossRefPubMed
12.
13.
go back to reference Su G, Mi S, Tao H, Li Z, Yang H, Zheng H, Zhou Y, Ma C. Association of glycemic variability and the presence and severity of coronary artery disease in patients with type 2 diabetes. Cardiovasc Diabetol. 2011;10:19.CrossRefPubMedPubMedCentral Su G, Mi S, Tao H, Li Z, Yang H, Zheng H, Zhou Y, Ma C. Association of glycemic variability and the presence and severity of coronary artery disease in patients with type 2 diabetes. Cardiovasc Diabetol. 2011;10:19.CrossRefPubMedPubMedCentral
14.
go back to reference Siegelaar SE, Kerr L, Jacober SJ, Devries JH. A decrease in glucose variability does not reduce cardiovascular event rates in type 2 diabetic patients after acute myocardial infarction: a reanalysis of the HEART2D study. Diabetes Care. 2011;34(4):855–7.CrossRefPubMedPubMedCentral Siegelaar SE, Kerr L, Jacober SJ, Devries JH. A decrease in glucose variability does not reduce cardiovascular event rates in type 2 diabetic patients after acute myocardial infarction: a reanalysis of the HEART2D study. Diabetes Care. 2011;34(4):855–7.CrossRefPubMedPubMedCentral
15.
go back to reference Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gotzsche PC, Ioannidis JP, Clarke M, Devereaux PJ, Kleijnen J, Moher D. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. J Clin Epidemiol. 2009;62(10):e1–34.CrossRefPubMed Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gotzsche PC, Ioannidis JP, Clarke M, Devereaux PJ, Kleijnen J, Moher D. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. J Clin Epidemiol. 2009;62(10):e1–34.CrossRefPubMed
16.
go back to reference Jung HS. Clinical implications of glucose variability: chronic complications of diabetes. Endocrinology and metabolism (Seoul, Korea). 2015;30(2):167–74.CrossRef Jung HS. Clinical implications of glucose variability: chronic complications of diabetes. Endocrinology and metabolism (Seoul, Korea). 2015;30(2):167–74.CrossRef
17.
go back to reference Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ (Clinical research ed). 2003;327(7414):557–60.CrossRef Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ (Clinical research ed). 2003;327(7414):557–60.CrossRef
18.
go back to reference Egger M, Smith GD, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. Br Med J. 1997;315(7109):629–34.CrossRef Egger M, Smith GD, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. Br Med J. 1997;315(7109):629–34.CrossRef
19.
go back to reference Bao YQ, Zhou J, Zhou M, Cheng YJ, Lu W, Pan XP, Tang JL, Lu HJ, Jia WP. Glipizide controlled-release tablets, with or without acarbose, improve glycaemic variability in newly diagnosed type 2 diabetes. Clin Exp Pharmacol Physiol. 2010;37(5–6):564–8.CrossRefPubMed Bao YQ, Zhou J, Zhou M, Cheng YJ, Lu W, Pan XP, Tang JL, Lu HJ, Jia WP. Glipizide controlled-release tablets, with or without acarbose, improve glycaemic variability in newly diagnosed type 2 diabetes. Clin Exp Pharmacol Physiol. 2010;37(5–6):564–8.CrossRefPubMed
20.
go back to reference Zhou SJ. The impact of glucose fluctuation on coronary arery disease severity in type 2 DM[Master], Shanxi Medical University; 2012. Zhou SJ. The impact of glucose fluctuation on coronary arery disease severity in type 2 DM[Master], Shanxi Medical University; 2012.
21.
go back to reference Nalysnyk L, Hernandez-Medina M, Krishnarajah G. Glycaemic variability and complications in patients with diabetes mellitus: evidence from a systematic review of the literature. Diabetes Obes Metab. 2010;12(4):288–98.CrossRefPubMed Nalysnyk L, Hernandez-Medina M, Krishnarajah G. Glycaemic variability and complications in patients with diabetes mellitus: evidence from a systematic review of the literature. Diabetes Obes Metab. 2010;12(4):288–98.CrossRefPubMed
22.
go back to reference Brohall G, Oden A, Fagerberg B. Carotid artery intima-media thickness in patients with type 2 diabetes mellitus and impaired glucose tolerance: a systematic review. Diabetic medicine : a journal of the British Diabetic Association. 2006;23(6):609–16.CrossRef Brohall G, Oden A, Fagerberg B. Carotid artery intima-media thickness in patients with type 2 diabetes mellitus and impaired glucose tolerance: a systematic review. Diabetic medicine : a journal of the British Diabetic Association. 2006;23(6):609–16.CrossRef
23.
go back to reference Tehrani DM, Wong ND. Integrating biomarkers and imaging for cardiovascular disease risk assessment in diabetes. Current cardiology reports. 2016;18(11):105.CrossRefPubMed Tehrani DM, Wong ND. Integrating biomarkers and imaging for cardiovascular disease risk assessment in diabetes. Current cardiology reports. 2016;18(11):105.CrossRefPubMed
24.
go back to reference Lorenz MW, Markus HS, Bots ML, Rosvall M, Sitzer M. Prediction of clinical cardiovascular events with carotid intima-media thickness: a systematic review and meta-analysis. Circulation. 2007;115(4):459–67.CrossRefPubMed Lorenz MW, Markus HS, Bots ML, Rosvall M, Sitzer M. Prediction of clinical cardiovascular events with carotid intima-media thickness: a systematic review and meta-analysis. Circulation. 2007;115(4):459–67.CrossRefPubMed
25.
go back to reference Wang C, Jin R, Nanda A, Yan J, Li G. Platelet PI3Kgamma contributes to carotid Intima-media thickening under severely reduced flow conditions. PLoS One. 2015;10(6):e0129265.CrossRefPubMedPubMedCentral Wang C, Jin R, Nanda A, Yan J, Li G. Platelet PI3Kgamma contributes to carotid Intima-media thickening under severely reduced flow conditions. PLoS One. 2015;10(6):e0129265.CrossRefPubMedPubMedCentral
26.
go back to reference Zineldeen DH, Keshk WA, Ghazy AH, El-Barbary AM. Sucrose non-fermenting AMPK related kinase/Pentraxin 3 and DNA damage axis: a gateway to cardiovascular disease in systemic lupus erythematosus among Egyptian patients. Ann Clin Biochem. 2016;53(2):240–51.CrossRefPubMed Zineldeen DH, Keshk WA, Ghazy AH, El-Barbary AM. Sucrose non-fermenting AMPK related kinase/Pentraxin 3 and DNA damage axis: a gateway to cardiovascular disease in systemic lupus erythematosus among Egyptian patients. Ann Clin Biochem. 2016;53(2):240–51.CrossRefPubMed
27.
go back to reference Bonora E, Formentini G, Calcaterra F, Lombardi S, Marini F, Zenari L, Saggiani F, Poli M, Perbellini S, Raffaelli A, et al. HOMA-estimated insulin resistance is an independent predictor of cardiovascular disease in type 2 diabetic subjects - prospective data from the Verona diabetes complicated study. Diabetes Care. 2002;25(7):1135–41.CrossRefPubMed Bonora E, Formentini G, Calcaterra F, Lombardi S, Marini F, Zenari L, Saggiani F, Poli M, Perbellini S, Raffaelli A, et al. HOMA-estimated insulin resistance is an independent predictor of cardiovascular disease in type 2 diabetic subjects - prospective data from the Verona diabetes complicated study. Diabetes Care. 2002;25(7):1135–41.CrossRefPubMed
28.
go back to reference Rask-Madsen C, Buonomo E, Li Q, Park K, Clermont AC, Yerokun O, Rekhter M, King GL. Hyperinsulinemia does not change atherosclerosis development in apolipoprotein E null mice. Arterioscler Thromb Vasc Biol. 2012;32(5):1124–31.CrossRefPubMedPubMedCentral Rask-Madsen C, Buonomo E, Li Q, Park K, Clermont AC, Yerokun O, Rekhter M, King GL. Hyperinsulinemia does not change atherosclerosis development in apolipoprotein E null mice. Arterioscler Thromb Vasc Biol. 2012;32(5):1124–31.CrossRefPubMedPubMedCentral
29.
go back to reference Bringhenti I, Ornellas F, Mandarim-de-Lacerda CA, Aguila MB. The insulin-signaling pathway of the pancreatic islet is impaired in adult mice offspring of mothers fed a high-fat diet. Nutrition (Burbank, Los Angeles County, Calif). 2016;32(10):1138–43.CrossRef Bringhenti I, Ornellas F, Mandarim-de-Lacerda CA, Aguila MB. The insulin-signaling pathway of the pancreatic islet is impaired in adult mice offspring of mothers fed a high-fat diet. Nutrition (Burbank, Los Angeles County, Calif). 2016;32(10):1138–43.CrossRef
30.
go back to reference Guilherme A, Virbasius JV, Puri V, Czech MP. Adipocyte dysfunctions linking obesity to insulin resistance and type 2 diabetes. Nat Rev Mol Cell Biol. 2008;9(5):367–77.CrossRefPubMedPubMedCentral Guilherme A, Virbasius JV, Puri V, Czech MP. Adipocyte dysfunctions linking obesity to insulin resistance and type 2 diabetes. Nat Rev Mol Cell Biol. 2008;9(5):367–77.CrossRefPubMedPubMedCentral
31.
go back to reference Mu P, Lu H, Zhang G, Chen Y, Fu J, Wang M, Shu J, Zeng L. Comparison of fasting capillary glucose variability between insulin glargine and NPH. Diabetes Res Clin Pract. 2011;91:e4–7.CrossRefPubMed Mu P, Lu H, Zhang G, Chen Y, Fu J, Wang M, Shu J, Zeng L. Comparison of fasting capillary glucose variability between insulin glargine and NPH. Diabetes Res Clin Pract. 2011;91:e4–7.CrossRefPubMed
32.
go back to reference Yoo HJ, An HG, Park SY, Ryu OH, Kim HY, Seo JA, Hong EG, Shin DH, Kim YH, Kim SG, et al. Use of a real time continuous glucose monitoring system as a motivational device for poorly controlled type 2 diabetes. Diabetes Res Clin Pract. 2008;82(1):73–9.CrossRefPubMed Yoo HJ, An HG, Park SY, Ryu OH, Kim HY, Seo JA, Hong EG, Shin DH, Kim YH, Kim SG, et al. Use of a real time continuous glucose monitoring system as a motivational device for poorly controlled type 2 diabetes. Diabetes Res Clin Pract. 2008;82(1):73–9.CrossRefPubMed
33.
go back to reference Su G, Su J, Wang L, et al. Effect of aerobic exercise training on glycemic variability and islet βcell function in type 2 diabetes mellitus in early stage. Jiangsu Med J. 2014(02):180–2. Su G, Su J, Wang L, et al. Effect of aerobic exercise training on glycemic variability and islet βcell function in type 2 diabetes mellitus in early stage. Jiangsu Med J. 2014(02):180–2.
34.
go back to reference Lin SD, Wang JS, Hsu SR, Sheu WH, Tu ST, Lee IT, Su SL, Lin SY, Wang SY, Hsieh MC. The beneficial effect of alpha-glucosidase inhibitor on glucose variability compared with sulfonylurea in Taiwanese type 2 diabetic patients inadequately controlled with metformin: preliminary data. J Diabetes Complicat. 2011;25(5):332–8.CrossRefPubMed Lin SD, Wang JS, Hsu SR, Sheu WH, Tu ST, Lee IT, Su SL, Lin SY, Wang SY, Hsieh MC. The beneficial effect of alpha-glucosidase inhibitor on glucose variability compared with sulfonylurea in Taiwanese type 2 diabetic patients inadequately controlled with metformin: preliminary data. J Diabetes Complicat. 2011;25(5):332–8.CrossRefPubMed
35.
go back to reference Yuan G, Hu H, Wang S, Yang Q, Yu S, Sun W, Qian W, Mao C, Zhou L, Chen D, et al. Improvement of beta-cell function ameliorated glycemic variability in patients with newly diagnosed type 2 diabetes after short-term continuous subcutaneous insulin infusion or in combination with sitagliptin treatment: a randomized control trial. Endocr J. 2015;62(9):817–34.CrossRefPubMed Yuan G, Hu H, Wang S, Yang Q, Yu S, Sun W, Qian W, Mao C, Zhou L, Chen D, et al. Improvement of beta-cell function ameliorated glycemic variability in patients with newly diagnosed type 2 diabetes after short-term continuous subcutaneous insulin infusion or in combination with sitagliptin treatment: a randomized control trial. Endocr J. 2015;62(9):817–34.CrossRefPubMed
36.
go back to reference Sun W, Zeng C, Liao L, Chen J, Wang Y. Comparison of acarbose and metformin therapy in newly diagnosed type 2 diabetic patients with overweight and/or obesity. Curr. Med. Res. Opin. 2016;32(8):1389–96. Sun W, Zeng C, Liao L, Chen J, Wang Y. Comparison of acarbose and metformin therapy in newly diagnosed type 2 diabetic patients with overweight and/or obesity. Curr. Med. Res. Opin. 2016;32(8):1389–96.
37.
go back to reference Kim HS, Shin JA, Lee SH, Kim ES, Cho JH, Son HY, Yoon KH. A comparative study of the effects of a dipeptidyl peptidase-IV inhibitor and sulfonylurea on glucose variability in patients with type 2 diabetes with inadequate glycemic control on metformin. Diabetes Technol Ther. 2013;15(10):810–6.CrossRefPubMed Kim HS, Shin JA, Lee SH, Kim ES, Cho JH, Son HY, Yoon KH. A comparative study of the effects of a dipeptidyl peptidase-IV inhibitor and sulfonylurea on glucose variability in patients with type 2 diabetes with inadequate glycemic control on metformin. Diabetes Technol Ther. 2013;15(10):810–6.CrossRefPubMed
38.
go back to reference Natale C, Annuzzi G, Bozzetto L, Mazzarella R, Costabile G, Ciano O, Riccardi G, Rivellese AA. Effects of a plant-based high-carbohydrate/high-fiber diet versus high-monounsaturated fat/low-carbohydrate diet on postprandial lipids in type 2 diabetic patients. Diabetes Care. 2009;32:2168–73.CrossRefPubMedPubMedCentral Natale C, Annuzzi G, Bozzetto L, Mazzarella R, Costabile G, Ciano O, Riccardi G, Rivellese AA. Effects of a plant-based high-carbohydrate/high-fiber diet versus high-monounsaturated fat/low-carbohydrate diet on postprandial lipids in type 2 diabetic patients. Diabetes Care. 2009;32:2168–73.CrossRefPubMedPubMedCentral
39.
go back to reference Cho JH, Chang SA, Kwon HS, Choi YH, Ko SH, Moon SD, Yoo SJ, Song KH, Son HS, Kim HS, et al. Long-term effect of the internet-based glucose monitoring system on HbA1c reduction and glucose stability: a 30-month follow-up study for diabetes management with a ubiquitous medical care system. Diabetes Care. 2006;29(12):2625–31.CrossRefPubMed Cho JH, Chang SA, Kwon HS, Choi YH, Ko SH, Moon SD, Yoo SJ, Song KH, Son HS, Kim HS, et al. Long-term effect of the internet-based glucose monitoring system on HbA1c reduction and glucose stability: a 30-month follow-up study for diabetes management with a ubiquitous medical care system. Diabetes Care. 2006;29(12):2625–31.CrossRefPubMed
40.
go back to reference Bibra H, Siegmund T, Kingreen I, Riemer M, Schuster T, Schumm-Draeger PM. Effects of analogue insulin in multiple daily injection therapy of type 2 diabetes on postprandial glucose control and cardiac function compared to human insulin: a randomized controlled long-term study. Cardiovasc Diabetol. 2016;15 Bibra H, Siegmund T, Kingreen I, Riemer M, Schuster T, Schumm-Draeger PM. Effects of analogue insulin in multiple daily injection therapy of type 2 diabetes on postprandial glucose control and cardiac function compared to human insulin: a randomized controlled long-term study. Cardiovasc Diabetol. 2016;15
41.
go back to reference Buse JB, Rodbard HW, Trescoli Serrano C, Luo J, Ivanyi T, Bue-Valleskey J, Hartman ML, Carey MA, Chang AM. Randomized clinical trial comparing basal insulin Peglispro and insulin Glargine in patients with type 2 diabetes previously treated with basal insulin: IMAGINE 5. Diabetes Care. 2016;39(1):92–100.CrossRefPubMed Buse JB, Rodbard HW, Trescoli Serrano C, Luo J, Ivanyi T, Bue-Valleskey J, Hartman ML, Carey MA, Chang AM. Randomized clinical trial comparing basal insulin Peglispro and insulin Glargine in patients with type 2 diabetes previously treated with basal insulin: IMAGINE 5. Diabetes Care. 2016;39(1):92–100.CrossRefPubMed
42.
go back to reference Mita T, Katakami N, Yoshii H, Onuma T, Kaneto H, Osonoi T, Shiraiwa T, Kosugi K, Umayahara Y, Yamamoto T, et al. Alogliptin, a Dipeptidyl peptidase 4 inhibitor, prevents the progression of carotid atherosclerosis in patients with type 2 diabetes: the study of preventive effects of Alogliptin on diabetic atherosclerosis (SPEAD-A). Diabetes Care. 2016;39(1):139–48.CrossRefPubMed Mita T, Katakami N, Yoshii H, Onuma T, Kaneto H, Osonoi T, Shiraiwa T, Kosugi K, Umayahara Y, Yamamoto T, et al. Alogliptin, a Dipeptidyl peptidase 4 inhibitor, prevents the progression of carotid atherosclerosis in patients with type 2 diabetes: the study of preventive effects of Alogliptin on diabetic atherosclerosis (SPEAD-A). Diabetes Care. 2016;39(1):139–48.CrossRefPubMed
43.
go back to reference Tay J, Luscombe-Marsh ND, Thompson CH, Noakes M, Buckley JD, Wittert GA, Yancy WS Jr, Brinkworth GD. A very low-carbohydrate, low-saturated fat diet for type 2 diabetes management: a randomized trial. Diabetes Care. 2014;37(11):2909–18.CrossRefPubMed Tay J, Luscombe-Marsh ND, Thompson CH, Noakes M, Buckley JD, Wittert GA, Yancy WS Jr, Brinkworth GD. A very low-carbohydrate, low-saturated fat diet for type 2 diabetes management: a randomized trial. Diabetes Care. 2014;37(11):2909–18.CrossRefPubMed
44.
go back to reference Tay J, Luscombe-Marsh ND, Thompson CH, Noakes M, Buckley JD, Wittert GA, Yancy WS Jr, Brinkworth GD. Comparison of low- and high-carbohydrate diets for type 2 diabetes management: a randomized trial. Am J Clin Nutr. 2015;102(4):780–90.CrossRefPubMed Tay J, Luscombe-Marsh ND, Thompson CH, Noakes M, Buckley JD, Wittert GA, Yancy WS Jr, Brinkworth GD. Comparison of low- and high-carbohydrate diets for type 2 diabetes management: a randomized trial. Am J Clin Nutr. 2015;102(4):780–90.CrossRefPubMed
45.
go back to reference Wan H, Zhao D, Shen J, Lu L, Zhang T, Chen Z. Comparison of the effects of continuous subcutaneous insulin infusion and add-on therapy with sitagliptin in patients with newly diagnosed type 2 diabetes mellitus. In: Journal of Diabetes Research vol. 2016;2016 Wan H, Zhao D, Shen J, Lu L, Zhang T, Chen Z. Comparison of the effects of continuous subcutaneous insulin infusion and add-on therapy with sitagliptin in patients with newly diagnosed type 2 diabetes mellitus. In: Journal of Diabetes Research vol. 2016;2016
46.
go back to reference Huang Z. The effect and comparison of Atorvastatin and itavastatin on blood lipids and blood glucose in elderly type 2 diabetic patients[master]: Central South University; 2012. Huang Z. The effect and comparison of Atorvastatin and itavastatin on blood lipids and blood glucose in elderly type 2 diabetic patients[master]: Central South University; 2012.
47.
go back to reference Zhou Q. Clinic study on insulin pump curing type 2 diabetes mellitus[master]. China: Jilin University; 2008. Zhou Q. Clinic study on insulin pump curing type 2 diabetes mellitus[master]. China: Jilin University; 2008.
48.
go back to reference Ye YZ. Research on the relationship between glucose fluctuations and oxidative stress in newly diagnosed type 2 diabetes mellitus[master]: Dalian Medical University; 2014. Ye YZ. Research on the relationship between glucose fluctuations and oxidative stress in newly diagnosed type 2 diabetes mellitus[master]: Dalian Medical University; 2014.
49.
go back to reference HE RT, LU Xiao F, WU JX, et al. A retrospective study on the risk of long-term albuminuria in newly diagnosed type 2 diabetic patients after continuous subcutaneous insulin infusion therapy. Chin J Diabetes. 2016;03:210–3. HE RT, LU Xiao F, WU JX, et al. A retrospective study on the risk of long-term albuminuria in newly diagnosed type 2 diabetic patients after continuous subcutaneous insulin infusion therapy. Chin J Diabetes. 2016;03:210–3.
50.
go back to reference Wang RP, Lou J, Hu YW, Liu JP, Zhang QY. Effect of different medical nutrition therapy on blood glucose fluctuation in elderly type 2 diabetes mellitus patients. Chongqing Medicine. 2015;28:3921–4. Wang RP, Lou J, Hu YW, Liu JP, Zhang QY. Effect of different medical nutrition therapy on blood glucose fluctuation in elderly type 2 diabetes mellitus patients. Chongqing Medicine. 2015;28:3921–4.
Metadata
Title
Glucose variability for cardiovascular risk factors in type 2 diabetes: a meta-analysis
Authors
Shuang Liang
Hang Yin
Chunxiang Wei
Linjun Xie
Hua He
Xiaoquan Liu
Publication date
01-12-2017
Publisher
BioMed Central
Published in
Journal of Diabetes & Metabolic Disorders / Issue 1/2017
Electronic ISSN: 2251-6581
DOI
https://doi.org/10.1186/s40200-017-0323-5

Other articles of this Issue 1/2017

Journal of Diabetes & Metabolic Disorders 1/2017 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.